Upgrade to SI Premium - Free Trial

Novartis' Beovu Label a Positive for Regeneron Pharma (REGN) - BMO

October 8, 2019 12:24 PM
BMO Capital analyst Matthew Luchini reiterated a Market Perform rating and $344.00 price target on Regeneron Pharma (NASDAQ: REGN), saying ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles